Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MGTX |
---|---|---|
09:32 ET | 242 | 4.13 |
09:34 ET | 5500 | 4.1001 |
09:36 ET | 200 | 4.115 |
09:38 ET | 1430 | 4.13 |
09:39 ET | 100 | 4.125 |
09:41 ET | 25748 | 4.11 |
09:43 ET | 5537 | 4.11 |
09:45 ET | 528 | 4.1 |
09:52 ET | 832 | 4.16 |
09:54 ET | 300 | 4.14 |
09:56 ET | 2250 | 4.095 |
09:57 ET | 600 | 4.0903 |
09:59 ET | 3700 | 4.08 |
10:06 ET | 51192 | 4.1 |
10:08 ET | 100 | 4.115 |
10:10 ET | 100 | 4.1 |
10:14 ET | 2328 | 4.17 |
10:17 ET | 240 | 4.165 |
10:21 ET | 100 | 4.165 |
10:24 ET | 500 | 4.15 |
10:28 ET | 200 | 4.165 |
10:30 ET | 900 | 4.15 |
10:32 ET | 200 | 4.15 |
10:33 ET | 100 | 4.16 |
10:35 ET | 100 | 4.16 |
10:39 ET | 100 | 4.17 |
10:42 ET | 1242 | 4.17 |
10:44 ET | 300 | 4.17 |
10:46 ET | 217 | 4.17 |
10:50 ET | 300 | 4.18 |
10:51 ET | 3891 | 4.23 |
10:53 ET | 1050 | 4.19 |
10:55 ET | 100 | 4.19 |
11:02 ET | 100 | 4.205 |
11:04 ET | 100 | 4.23 |
11:08 ET | 100 | 4.24 |
11:09 ET | 800 | 4.225 |
11:15 ET | 400 | 4.21 |
11:20 ET | 100 | 4.22 |
11:24 ET | 100 | 4.22 |
11:26 ET | 1532 | 4.21 |
11:27 ET | 200 | 4.195 |
11:36 ET | 504 | 4.2 |
11:38 ET | 200 | 4.21 |
11:40 ET | 200 | 4.22 |
11:42 ET | 200 | 4.23 |
11:44 ET | 1406 | 4.23 |
11:47 ET | 500 | 4.22 |
11:51 ET | 300 | 4.22 |
11:58 ET | 300 | 4.23 |
12:00 ET | 1489 | 4.22 |
12:02 ET | 100 | 4.21 |
12:14 ET | 400 | 4.225 |
12:16 ET | 958 | 4.22 |
12:18 ET | 2456 | 4.18 |
12:23 ET | 300 | 4.18 |
12:25 ET | 200 | 4.19 |
12:30 ET | 100 | 4.1999 |
12:32 ET | 200 | 4.199 |
12:34 ET | 800 | 4.19 |
12:36 ET | 704 | 4.19 |
12:38 ET | 300 | 4.18 |
12:39 ET | 406 | 4.18 |
12:41 ET | 200 | 4.175 |
12:45 ET | 661 | 4.165 |
12:52 ET | 513 | 4.18 |
12:56 ET | 100 | 4.18 |
12:59 ET | 1400 | 4.17 |
01:01 ET | 244 | 4.17 |
01:03 ET | 300 | 4.17 |
01:06 ET | 100 | 4.15 |
01:14 ET | 100 | 4.15 |
01:15 ET | 300 | 4.16 |
01:17 ET | 300 | 4.16 |
01:21 ET | 506 | 4.18 |
01:24 ET | 789 | 4.17 |
01:26 ET | 300 | 4.1755 |
01:32 ET | 100 | 4.18 |
01:35 ET | 1648 | 4.155 |
01:37 ET | 300 | 4.16 |
01:46 ET | 736 | 4.17 |
01:48 ET | 100 | 4.17 |
01:51 ET | 200 | 4.18 |
01:53 ET | 200 | 4.2 |
01:55 ET | 300 | 4.205 |
01:57 ET | 1516 | 4.2 |
02:06 ET | 300 | 4.2 |
02:08 ET | 800 | 4.195 |
02:09 ET | 234 | 4.19 |
02:18 ET | 100 | 4.205 |
02:22 ET | 101 | 4.2 |
02:24 ET | 384 | 4.215 |
02:26 ET | 300 | 4.22 |
02:27 ET | 435 | 4.22 |
02:29 ET | 1901 | 4.2 |
02:33 ET | 333 | 4.205 |
02:42 ET | 100 | 4.22 |
02:44 ET | 100 | 4.22 |
02:45 ET | 100 | 4.23 |
02:47 ET | 100 | 4.23 |
02:49 ET | 322 | 4.23 |
02:51 ET | 200 | 4.23 |
02:54 ET | 200 | 4.24 |
02:56 ET | 2375 | 4.2 |
03:00 ET | 500 | 4.2 |
03:03 ET | 100 | 4.195 |
03:05 ET | 100 | 4.2 |
03:07 ET | 100 | 4.205 |
03:09 ET | 1326 | 4.2 |
03:14 ET | 100 | 4.195 |
03:16 ET | 1655 | 4.18 |
03:21 ET | 200 | 4.18 |
03:25 ET | 200 | 4.19 |
03:27 ET | 100 | 4.19 |
03:30 ET | 444 | 4.2 |
03:32 ET | 2334 | 4.21 |
03:34 ET | 3638 | 4.2 |
03:36 ET | 100 | 4.2 |
03:38 ET | 100 | 4.205 |
03:41 ET | 200 | 4.21 |
03:43 ET | 3080 | 4.21 |
03:45 ET | 100 | 4.2 |
03:48 ET | 1009 | 4.195 |
03:50 ET | 300 | 4.2 |
03:52 ET | 1948 | 4.22 |
03:54 ET | 3942 | 4.22 |
03:56 ET | 400 | 4.215 |
03:57 ET | 1943 | 4.225 |
03:59 ET | 59737 | 4.23 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
MeiraGTx Holdings PLC | 320.3M | -2.8x | --- |
Iteos Therapeutics Inc | 365.2M | -3.3x | --- |
XOMA Royalty Corp | 317.7M | -12.3x | --- |
Corvus Pharmaceuticals Inc | 318.4M | -11.8x | --- |
Monte Rosa Therapeutics Inc | 325.3M | -2.4x | --- |
Inozyme Pharma Inc | 314.9M | -3.5x | --- |
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $326.5M |
---|---|
Revenue (TTM) | $8.1M |
Shares Outstanding | 77.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.29 |
EPS | $-1.49 |
Book Value | $2.17 |
P/E Ratio | -2.8x |
Price/Sales (TTM) | 40.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,083.19% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.